Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Which means regen is trading at $5
5m here. The risk & reward too good to be ignored. Tgt 0.05 which based on regen mkt cap of 250m with hex orphan status phase 1 trial.
BMSN lousy stock. Must scold you then will move is it? :)
Nice breakout.
Wow look at the volume 66m. What is going on here
Trading halt?
BMSN will fly. 0.05 is all that i ask for
When will ino start trading? It seems the symbol not valid anymore.
Good volume. Next week the show will start
Today doji closing likely n tomorrow till next week power up.
Today could be a doji. Follow by another one long bar up tomorrow
Hold tight. Fda approval coming. Focus
Clap clap
Lets guess what is the closing
Risk & reward too good to be true! Go BMSN go...
BMSN offer the best risk & reward ratio. I m looking at least at 1:10 return. Do your own calculation, is that simple and you wont be so worry about day to day price action. Sit tight and wait patiencly for the news
Risk & Reward too good. What r the downside risk n what r the potential return
Once the fDA approval there will be a lot of publicity n regen will be everywhere in media n conferences presenting their research n PPS will pop.
What is the ratio?
Take it with a pinch of salt then
Ebd of june early july
6 to 8 weeks according to dr kim
9mth endpoint is very promising compare to placebo.
VGX-3100 Phase II Study
•Placebo-controlled, randomized, doubled blind
•148+ subjects: females 18-55 •Histologically confirmed HPV16 or 18-associated CIN 2/3 or 3
•3:1 VGX-3100/electroporation vs. placebo/electroporation
•Two plasmids: Type 16 and Type 18, each encoded for E6/E7 antigens; 3 mg/ml per plasmid; treatment at months 0, 1, 3
•Primary endpoint month 9
•Regression of CIN 2/3 to CIN 1 or less •80% powered for 27% increase relative to natural regression (25% assumption) in placebo group, i.e 52%
•Secondary endpoints
•Clearance of HPV 16 or 18 •Immunogenicity
•Safety
According to dr kim he is positive on the progress of the phase 2 after getting feedback from the panel.
Yup...go bmsn
Actually you cant make much just by going thru licensing. I would rather like to see it go thru phase 3 n commercialise and that is where the real meat. You can have a lot of product in the pipeline but you just need one good product commercialise and the rest either sell or do licensing to fund this phase 3 trial.
Dirt cheap. Buy n hold. Risk n reward is good
Agreed!. Risk n reward is good. Easily double
Dirt cheap better buy
Better add more b4 the big news out. Risk & rewards is good
Wow cheap again for me to collect
Today met Dr Kim in person confirm the share consolidation voting during the agm
Good.
It will be good fda approval come with orphanage status. This will give the ppps a big boost
As i say b4 risk & reward for this stock is very good. No pain no gain!
Wow BMSN makes me high!
So what is the average cost of Koos holding over the years
Thanks. BMSN diluted so much over the years.
More upside. The pullback volume is thin. Pretty confident it will run up again